Retroelements constitute a large part of the human genome. These sequences are mostly silenced in normal cells, but genome-wide DNA hypomethylation in cancers might lead to their re-expression. Whether this re-expression really occurs in human cancers is largely unkown. We therefore investigated expression and DNA methylation of several classes of retroelements in human prostate cancer tissues and cell lines by quantitative reverse transcription-polymerase chain reaction and pyrosequencing, respectively. The most striking finding was strong and generalized increased expression of the HERV-K_22q11.23 provirus in cancers, including de novo expression of a spliced accessory Np9 transcript in some tumors. In parallel, DNA methylation in the long terminal repeat (LTR) decreased. Conversely, HERVK17 expression was significantly diminished in cancer tissues, but this decrease was unrelated to LTR methylation. Expression of both proviruses was restricted to androgen-responsive prostate cancer cell lines and LTRs sequences containing steroid hormone-responsive elements bound the androgen receptor and conferred androgen responsiveness to reporter constructs. Expression of LINE-1 5#-untranslated region (UTR) and 3#-UTR sequences in prostate cancers rather decreased, despite significant hypomethylation of the internal LINE-1 promoter. Increased expression of the young AluYa5 and AluYb8 families was restricted to individual tumors. Our findings demonstrate a surprising specificity of changes in expression and DNA methylation of retroelements in prostate cancer. In particular, LINE-1 hypomethylation does not lead to generalized overexpression, but specific human endogenous retrovirus-K proviruses display conspicuous changes in their expression hinting at significant functions during prostate carcinogenesis.
Introduction
Over 40% of the human genome is derived from retroelements. It contains remnants of several true retroviruses, such as human endogenous retroviruses (HERV) K and W as well as long-interspersed and short-interspersed non-LTR sequences represented mainly by LINE-1 and multiple Alu families, respectively (1) (2) (3) (4) . In the course of evolution, many retroelement sequences have been truncated and mutated. Some elements have been co-opted for physiological functions in genome organization and regulation of gene expression (3) . Nevertheless, many retroelements still harbor a potential to afflict damage on their host by insertion mutations, illegimate recombination and disturbances of gene expression. Their activities are therefore constrained by several mechanisms that range from DNA methylation and dense chromatin packaging to editing and sequestration of eventual transcripts (2, 4) . Hypomethylation of retroelements found in various cancers could therefore lead to their reactivation and consequently to disturbances of general gene expression and promotion of genomic instability (1) .
In prostate cancer, global hypomethylation of LINE-1 elements, correlating largely with an overall decrease of methylcytosine in total cellular DNA, is associated with cancer progression and most pronounced in metastatic cases (5) (6) (7) . It has been proposed that global hypomethylation in cancer might go along with reactivation of normally silenced retroelements, but the evidence is still sporadic. The best data are available for testicular germ cell cancers (8, 9) , whereas in prostate cancer, the issue has been little studied. Nevertheless, reports of translatable HERV-E env messenger RNA (mRNA) and antigenic HERV-K in some cases (10, 11) hint at activation of HERVs. HERV-K proviruses are also involved in chromosomal translocations that are presumably causative in prostate cancer. In these rare cases, chromosomal rearrangements create fusion genes in which the HERVK17 and HERV-K_22q11.23 proviruses become located apposite to the ETV1 gene leading to the abnormal expression of this ETS family transcription factor (12, 13) . Much more frequently, in about 30-60% of the tumors, the coding region of the gene encoding another ETS transcription factor, ERG, becomes fused to the regulatory region of the TMPRSS2 gene (14) . Since TMPRSS2 is strongly androgenresponsive, ERG is overexpressed in response to androgens in these prostate cancers. Intriguingly, expression of HERVK17 and HERVK_22q11.23 is also inducible by androgens in the prostate cancer cell line LNCaP (12, 13) .
We have conducted the first broad analysis of expression and DNA methylation of retroelements in prostate cancer cell lines and tissues, namely LINE-1 sequences, two young active Alu subfamilies (AluYa5 and AluYb8) and four different HERV-Ks, including the two proviruses occasionally involved in cancer-specific translocations.
Material and methods

Tissue samples and cell lines
The prostate carcinoma and benign tissue samples were a subset of those described previously (6) . In brief, 20 cancers were staged as pT2, 23 as pT3 and two as pT4, 26 tumors had a Gleason score of 7, 13 , 7 and 6 . 7. No case had distant metastases, but 11 cancers had metastasized to lymph nodes. Patient consent was obtained and the study approved by the Ethics Committee of the Medical Faculty of the Heinrich Heine University. The prostate carcinoma cell lines 22Rv1, DU-145, LNCaP, PC-3 and the embryonal carcinoma cell line NCCIT were cultured in RPMI-1640 (Gibco Life Technologies, Karlsruhe, Germany), supplemented with 10% fetal calf serum and 100 U/ml penicillin/ 100 lg streptomycin. The immortalized benign prostate hyperplasia cell line BPH-1 was cultured in RPMI-1640 supplemented with 5% fetal calf serum and penicillin/streptomycin. MDA PCa 2b was cultured in the recommended complex medium supplemented with testosterone as described (15) . Normal prostate epithelial cells (PrECs) purchased from Lonza (Verviers, Belgium) were cultured as recommended by the supplier.
Nucleic acids extraction and quantitative reverse transcription-polymerase chain reaction High molecular weight DNA and total RNA were extracted from identical powdered tissues as described previously (6) . Of note, RNA extraction involved acid phenol extraction followed by column purification to minimize DNA contamination. Synthesis of complementary DNA was performed using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany), according to the manufacturer's protocol, including an extra DNA removal step by DNase as recommended by the supplier. To ascertain the absence of genomic DNA, qualitative polymerase chain reaction (PCR) was performed using HotStarTaq DNA Polymerase (Qiagen) with a LINE-1 5# assay (supplementary Table I is available at Carcinogenesis Online), using 1 ll of a 1:10 dilution of the RNA aliquot before reverse transcription or LNCaP complementary DNA as a positive control. The PCR conditions were as following: initial denaturation step at 95°C for 10 min, followed by 35 amplification cycles consisting of denaturation at 94°C for 15 s, annealing at 56°C for 15 s and extension at 72°C for 30 s. Samples were analyzed on 2% agarose gels, where absence of a specific signal implied successful genomic DNA removal. Quantitative reverse transcription (qRT)-PCR was performed on a 7500 Fast Real-Time PCR System (Applied Biosystems, Carlsbad, CA) using QuantiTect SYBR Green PCR Kit (Qiagen). All qRT-PCR data were adjusted to TATA-box-binding protein (TBP) mRNAs measured by a specific QuantiTect assay (Qiagen). For all other transcripts, specifically designed primers (supplementary Table I is available at Carcinogenesis Online) were employed using the following PCR conditions: initial denaturation step at 95°C for 10 min, followed by 40 amplification cycles consisting of denaturation at 95°C for 15 s, annealing for 20 s and extension at 72°C for 30 s. All measurements were performed in at least duplicates; assay variance was ,10%. Relative expression was calculated by a modified DDCt method published by Pfaffl (16) .
Bisulfite treatment and DNA methylation analyses DNA was bisulfite modified using the EZ DNA Methylation-Gold Kit (Zymo Research, Hiss Diagnostics, Freiburg, Germany) according to the manufacturer's instructions. Bisulfite-treated DNA samples were used for PCR with the indicated primers (supplementary Table I is available at Carcinogenesis Online) using the following conditions: initial denaturation step at 95°C for 10 min, followed by 45 amplification cycles consisting of denaturation at 95°C for 15 s, annealing for 20 s and extension at 72°C for 45 s. Pyrosequencing was carried out on a PyroMark Q24 instrument (Qiagen) according to manufacturer's instruction. Corresponding sequencing primers were listed in supplementary Table I , available at Carcinogenesis Online. Methylation values were calculated as the mean value of 4 (LINE-1) or 6 (HERV-K_22q11.23; HERVK17) CpG sites, respectively. Conventional bisulfite sequencing with cloning of PCR products was performed as described (6) using primers listed in supplementary Table I , available at Carcinogenesis Online.
Chromatin immunoprecipitation and quantitative analysis of immunoprecipitated DNA Histone-chromatin immunoprecipitation (ChIP) was performed with the ChIP-IT Express Kit (#53008; Active Motif, Brusseles, Belgium) as described (17) . The bound ChIP fractions were quantified by real-time PCR amplification using SYBR Green PCR mix (Qiagen) and primer pairs as indicated (supplementary Table I is available at Carcinogenesis Online) with the following conditions: initial denaturation step at 95°C for 10 min, followed by 40 amplification cycles consisting of denaturation at 95°C for 15 s, annealing for 20 s and extension at 72°C for 30 s. The 'Input DNA' purified from the sheared unprecipitated chromatin was used for standardization. For histone-ChIP, normalization to GAPDH or CTCFL was done as described previously (17) . For androgen receptor ChIP, 10 lg chromatin of each sample were immunoprecipitated using 3 lg androgen receptor antibody (N-20; Santa Cruz Biotechnology, Heidelberg, Germany) followed by analogous DNA purification and quantitative PCR with primers listed in supplementary Table I , available at Carcinogenesis Online).
Transfection and luciferase assays
Promoter fragments were obtained using KOD Hot Start DNA Polymerase (EMD chemicals, Gibbstown, NJ) with the indicated primers (supplementary Table I is available at Carcinogenesis Online) and were cloned at MluI and XhoI sites into the pGL3basic vector (Promega, Mannheim, Germany). The p850-luciferase plasmid with a constitutive LINE-1 promoter (18) was used as a positive reference. The probasin promoter luciferase and androgen receptor expression plasmids have been described (19) . For transfection, 22Rv1 or PC-3 cells grown in 24-well plates were transfected using FuGene6 (Roche, Basel, Switzerland), according to the manufacturer's instructions. After 12 h in RPMI-1640 with 10% charcoal-stripped steroid-free fetal bovine serum (cFBS; Biowest, Nuaillé, France), the medium was changed to RPMI-1640 containing 2.5% cFBS, with or without 10 nM of the synthetic androgen R1881 (methyltrienolone; Sigma-Aldrich, Munich, Germany). Reporter activity was assessed after a further 48 h period using the Dual-Luciferase Reporter Assay System (Promega). Values were normalized to the p850-luciferase mean value.
Statistical analysis
The significance of statistical comparisons was evaluated by means of MannWhitney U-test. Correlation was determined using Spearman's rank correlation coefficient. In each calculation, a value of P ,0.05 was considered significant.
Results
Expression of retroelements in prostate cancer cell lines
We first measured retroelement (AluYa5 and AluYb8, LINE-1 5#-untranslated region (UTR) and 3#-UTR, HERV-K_22q11.23, HERVK17, HERV-K_11q23.3 and HERV-K22q11.21) transcript levels by qRT-PCR in prostate cancer cell lines (22Rv1, DU-145, LNCaP, MDA PCa 2B and PC-3) as well as in the SV40-immortalized benign prostate hyperplasia cell line BPH-1 and in a primary culture of normal PrECs. The embryonal carcinoma cell line NCCIT was included for comparison.
Our assays for AluYa5 and AluYb8 expression interrogate 140 and 115 elements, respectively. Expression was detectable in all cell lines as well as the PrEC culture ( Figure 1A) , with overall moderate differences. All prostate carcinoma cell lines, except 22Rv1, showed increased expression of AluYa5 compared with PrECs, whereas the differences in AluYb8 expression were less conspicuous.
As described recently (20) , intact LINE-1 elements generate spliced as well as full-length transcripts. We therefore designed qRT-PCR assays detecting either the 5#-UTR (100-345 nts) or the 3#-UTR (5807-5965 nts) of full-length LINE-1 elements [LINE-1_Hs consensus sequence Repbase15.10 (21)]. The 3#-assay detects spliced as well as unspliced LINE-1 transcripts, whereas the 5#-assay only detects 
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unspliced RNA because the reverse primer is located in the intronic sequence. According to in silico analyses using L1Base and the UCSC Genome Browser database (22, 23) , the 3#-assay amplifies transcripts from %2200 LINE-1s, of which 256 elements encode potentially functional ORF2 protein. The 5#-assay recognizes transcripts from %400 elements including 170 with intact ORF2.
LINE-1 displayed stronger expression differences among the cell lines than AluYs. Expression detected by the 5#-assay differed almost 10-fold between the weakly expressing PrECs and the maximally expressing prostate cancer cell line LNCaP. LINE-1 3# transcripts also showed a tendency toward higher expression in prostate carcinoma cell lines compared with PrECs.
Significant expression of HERV-K_22q11.23 was detected in the three androgen-responsive prostate cancer cell lines 22Rv1, LNCaP and MDA PCa 2b as well as NCCIT ( Figure 1B) . Interestingly, the MDA PCa 2b cell line displayed $300-fold more HERV-K_22q11.23 mRNA than LNCaP, where its expression was discovered (12) . Normal prostate cells and all cancer cell lines lacking a significant androgen response (PC-3, DU-145 and BPH-1) exhibited expression near the limit of detection. HERVK17 exhibited a similar expression pattern. Significant levels were found in 22Rv1, LNCaP and MDA PCa 2B with the highest expression again in MDA PCa 2b ( Figure 1C ). For HERVK17, other than HERV-K_22q11.23, a low but significant amount of mRNA was detected in the PrEC culture, whereas the androgen-non-responsive cell lines PC-3, DU-145 and BPH-1 again lacked expression. Expression of two further proviruses, HERVK_11q23.3 and HERV-K_22q.11.21, was only detectable in the NCCIT teratocarcinoma cell line (supplementary Figure 1 is available at Carcinogenesis Online).
DNA methylation at retroelements in prostate cancer cell lines Methylation at LINE-1, HERVK17 and HERV-K_22q11.23 retroelements was assessed by pyrosequencing of bisulfite-treated DNA using newly designed assays (see supplementary Figure 2A -C, available at Carcinogenesis Online, for example profiles). For LINE-1, the assay interrogates four CpGs in the CpG islet within the internal promoter of full-length consensus elements (LINE-1_Hs consensus sequence; 307-330 nt). LINE-1 methylation ranged in prostate cancer cell lines from 41.1% mean methylation in MDA PCa 2b to 79.3% in DU-145 (Table I ). In addition to MDA PCa 2b, 22Rv1 and LNCaP exhibited significantly lower mean methylation than PrECs, with 60.2% mean methylation. Interestingly, mean LINE-1 methylation was elevated in BPH-1, PC-3 and DU-145 compared with PrEC.
To investigate HERV-K methylation status, pyrosequencing assays were developed assessing six CpGs in the CpG islets of the 5#-LTRs of HERVK17 (chr17:7 901 131-7 901 183; NCBI/hg18) and HERVK_22q11. 23 (chr22:22 209 064-22 209 098; NCBI36/hg18). HERVK17 methylation was highly variable among the cell lines, ranging from ,3% in LNCaP to 70% in DU-145 (Table I) . Strongly elevated methylation was observed in BPH-1, PC-3 and DU-145 compared with PrECs, which showed 11.4% mean methylation. The HERVK17-expressing lines 22Rv1, LNCaP and MDA PCa 2b were essentially demethylated at the analyzed CpG sites.
HERV-K_22q11.23 mean CpG methylation was relatively stable among the cell lines with comparable values in PrECs, LNCaP and MDA PCa 2b (Table I ). An elevation by 10-12% was seen in BPH-1, PC-3 and DU-145. HERV-K_22q11.23 methylation was exceptionally low in 22Rv1 cells. This result was confirmed by conventional bisulfite sequencing (supplementary Figure 3 is available at Carcinogenesis Online).
Histone modifications at retroelements in prostate cancer cell lines To determine how chromatin status at retroelement sequences might correlate with their expression and CpG methylation, histone modifications at HERV-Ks and LINE-1 were analyzed by ChIP in LNCaP and PC-3, two cell lines representing high and low HERV-K and LINE-1 expression, respectively (Figure 1 ). The repressive H3K9me3 and H3K27me3 histone modifications were more prominent at HERV-K_22q11.23, HERVK17 and LINE-1 sequences in PC-3 than LNCaP, whereas the active modification H3K4me3 and to a lesser degree H3K9Ac were most enriched in LNCaP at the HERV-K_22q11.23 LTR (Figure 2 ). However, repressive modifications remained well detectable in LNCaP cells.
Trancript levels of retroelements in prostate cancer tissues
We subsequently measured retroelement expression in a well-characterized series of 45 cancerous and 11 benign prostate tissues (6) . The most striking finding was highly significantly (Mann-Whitney U-test; P , 0.001) elevated HERV-K_22q11.23 mRNA in almost all cancer tissues ( Figure 3 ). Our standard assay interrogates a first truncated 5#LTR/ gag region in this provirus ( Figure 3A) , similar to that used by others (12) . To characterize HERV-K_22q11.23 expression in more detail, additional assays were performed for the env region or the spliced RNA encoding the accessory protein Np9 ( Figure 3A) . Expression of the env region was likewise significantly elevated in cancers ( Figure 3C ; Mann-Whitney U-test; P 5 0.0071) correlating well with 5#-LTR/gag expression (Spearman's q 5 0.724; P , 0.001). The accessory transcript showed a more discriminate pattern being detectable only in a subset of the carcinomas (18/45), especially in those with more strongly elevated levels of the other transcripts ( Figure 3D ; MannWhitney U-test; P 5 0.017). Only a single benign tissue expressed the Np9 transcript. In the cell lines, it was only found in MDA PCa 2B and NCCIT exhibiting the highest overall HERV-K_22q11.23 expression (data not shown). Whereas HERV-K_22q11.23 became activated, expression of the HERVK17 provirus was significantly reduced in cancerous compared with benign tissue samples ( Figure 4A ; Mann-Whitney U-test; P 5 0.0025). As in the prostatic cell lines, the expression of HERVK_11q23.3 was undetectable in benign and cancerous prostate tissues (data not shown). Transcript levels of HERV-K_22q11.21 were therefore not assessed in the tissue samples because of the lack of expression in prostatic cell lines. Increased expression of HERV-K_22q11.23 in prostate cancers correlated well and highly significantly (Spearman q 5 0.556, P , 0.001) with expression of PSA/KLK3 mRNA. Similarly, HERVK17 expression was most strongly diminished in cancers with low PSA/KLK3 expression (Spearman q 5 0.551, P , 0.001).
Unexpectedly, LINE-1 transcript levels were decreased, slightly but significantly, in prostate cancer tissues with assays for either the 5#-or 3#-region (Figure 4B and C; Mann-Whitney U-test; P 5 0.027 and P 5 0.015). The two transcripts correlated strongly and highly significantly with each other in cancerous tissues (Spearman's q 5 0.800; P , 0.001), although no correlation was found in benign tissues (Spearman's q 5 À0.096; P 5 0.780). Together, these measurements indicate a shift toward unspliced transcripts with lower expression overall.
AluYa5 and AluYb8 mRNA levels were not significantly changed between benign and cancerous tissue samples overall ( Figure 4D and E). However, AluYb8 was overexpressed in several individual cancers.
Methylation changes at retroelements in prostate cancer tissues
Methylation of HERV-K_22q11.23, HERVK17 and LINE-1 sequences was quantified in the tissue series (45 cancerous and 11 benign samples) by pyrosequencing. Mean methylation of the HERVK_22q11.23 LTR CpG sites was highly significantly decreased (Mann-Whitney U-test; P , 0.001) in cancerous versus benign prostate tissues ( Figure 4F ). Decreased methylation correlated with increased expression of 5# LTR/gag-(Spearman's q 5 À0.516; P , 0.001) and env (Spearman's q 5 À0.447; P 5 0.0023) regions.
The HERVK17 CpG islet was methylated in benign prostate tissues at a mean level of 35.1% ( Figure 4G ). Methylation was moderately but significantly decreased in cancer tissues (Mann-Whitney U-test; P 5 0.0182). HERVK17 methylation and expression in the tissue samples did not correlate.
LINE-1 sequences have been described as hypomethylated in prostate cancer by our group and others. Our newly designed pyrosequencing assay likewise revealed a slight, but overall significant decrease in LINE-1 CpG methylation in prostate cancers compared with benign tissues ( Figure 4H ; Mann-Whitney U-test; P 5 0.0294). Intriguingly, LINE-1 methylation correlated with neither 5#-nor 3#-LINE-1 expression.
An overview of retroelement expression and methylation changes in prostate cancer cell lines and tissues can be found in the supplementary Table II , available at Carcinogenesis Online.
Regulation of HERV-K promoters by steroid hormone receptors
In silico analysis revealed potential steroid hormone receptor-binding sites (SRE) in the LTRs of several HERV-K LTRs. In particular, the 
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HERV-K_22q11.23 (H22q) and HERVK17 (H17) proviruses, expressed in the prostate, contained several such sites, whereas HERV-K_11q23.3 (H11q) expressed only in NCCIT cells contained only two potential sites. We therefore cloned the promoter sequences of each HERV-K into a luciferase expression vector and additionally generated truncated constructs lacking the predicted SREs. Each construct was transfected into 22Rv1 cells treated with or without the synthetic androgen R1881 (methyltrienolone). In these assays, the H22q-luc and H17-luc constructs showed strong basal expression, whereas H11q-luc was much weaker ( Figure 5A ). Treatment with R1881 lead to a small, but significant further increase of luciferase expression from H22q-luc (Mann-Whitney U-test; P , 0.01), and a stronger highly significant increase from the H17-luc construct (Mann-Whitney U-test; P , 0.01). A minimal but statistically significant increase was observed with the H11q reporter plasmid (Mann-Whitney U-test; P , 0.01). Importantly, deletion of the putative SREs abolished induction by R1881 for all three constructs.
Notably, basal luciferase expression in cells transfected with the truncated H11q promoter exhibited no significant difference compared with the full-length construct. In contrast, truncated H22q and especially H17 reporter constructs yielded strikingly lower luciferase expression compared with their full-length counterparts. As a control, R1881 strongly induced luciferase expression from the rat probasin promoter, as expected ( Figure 5A ).
In the PC-3 cell line, which lacks significant androgen receptor expression, luciferase expression from the H22q and H17 LTR reporter plasmids was lower than from H11q-luc and deletion of the SRE-containing region had little effect on promoter activity. Cotransfection with a plasmid expressing the androgen receptor conferred androgen responsiveness to a probasin promoter construct, but still none of the LTR reporters displayed increased activity in responce to R1881 ( Figure 5B ).
As measured by ChIP, bicalutamide treatment decreased binding of the androgen receptor to the LTRs of H22q and H17 in MDA PCa 2b Fig. 4 . Expression and DNA methylation of retrolements in prostate cancer tissues. RNA levels of HERVK17 provirus, LINE-1 5# and 3# regions, ALUYa5 and ALUYb8 were assessed in 11 benign and 45 prostate cancer tissues by qRT-PCR (A-E). DNA methylation in the CpG islets of LINE-1 and HERV-K LTRs were analyzed by pyrosequencing (F-H). Methylation is plotted as mean methylation value in percent. RNA levels were each standardized to the median RNA level of benign prostate tissues set as 1. P values were calculated by the Mann-Whitney U-test.
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cells (which are routinely cultured in testosterone-containing medium). Conversely, treatment of 22Rv1 cells with R1881 increased androgen receptor binding to the H17 LTRs, whereas the effect was weaker at H22q ( Figure 5C ). Comparable changes were observed at well-established androgen receptor-binding sites (24) in the TMPRSS2 and PSA/KLK3 genes ( Figure 5C ). No binding was detected at the RHO (rhodopsin) gene, used as a negative control (data not shown).
Since HERV-K_22q11.23 and HERVK17 are both androgen regulated, we wondered whether their expression and methylation might be affected by altered ERG expression in prostate cancer, which changes androgen responses. Expression of HERV-K_22q11.23 was significantly higher in the prostate cancer tissues with high ERG expression than the cases with low normal ERG expression [categorized as described in (25)], whereas no significant difference between the groups was observed for HERVK17 ( Figure 5D ). Accordingly, HERV-K_22q11.23 LTR methylation was significantly decreased (Mann-Whitney U-test; P 5 0.0032) in ERG-high cancers, whereas methylation of HERVK17 was unchanged (P 5 0.869).
Discussion
The most striking findings in our study are the pronounced and differential changes in the expression of specific HERV-K proviruses in prostate cancer. Proviruses of this family are expressed in a tissuespecific pattern, which is still incompletely characterized (26) (27) (28) . In our study, HERVK17 was expressed in prostatic cells but not in an embryonal carcinoma cell line, HERV-K_22q11.23 in both, whereas HERV-K_11q23.3 and HERV-K_22q11.21 transcripts were restricted to embryonal carcinoma cells, supporting the contention that these (24)].
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proviruses may be specifically expressed in germ cell tumors (28) . Prostatic expression of HERVK17 and HERV-K_22q11.23 and androgen responsiveness in LNCaP cells has been reported (12, 13) . We observed that their transcripts were essentially restricted to androgen-responsive prostate cancer cell lines and demonstrated that basal expression and regulation by androgens requires a segment in their LTRs containing steroid hormone response elements. Binding of the androgen receptor to that region was androgen dependent. The transcription factors controlling HERV LTRs and determining their tissue specificity are still poorly characterized (29) ; our data indicate that the androgen receptor may contribute to the prostate-specific expression of HERV-K proviruses.
Recently, chromosomal proximity of the TMPRSS2 gene with ETS family genes induced by androgen signaling was reported as an important step in the formation of recurrent TMPRSS2-ETS gene fusions in prostate cancer (30, 31) . By analogy, prostatic expression and androgen responsiveness might predispose HERV-K_22q11.23 and HERVK17 for participation in gene fusions. Each provirus has been detected as a part of a fusion gene with the ETS family ETV1 gene in a single prostate cancer case (12, 13) . Of note, the expression changes in our tissue series are most probably unrelated to ETV1 fusions since ETV1 expression was only elevated in five cancers (data not shown).
In prostate cancer tissues, HERV-K_22q11.23 was frequently overexpressed, whereas HERVK17 was downregulated in the majority of cases. Nevertheless, both proviruses appear to remain in principle androgen responsive as indicated by their expression pattern in prostate cancer cell lines, androgen-dependent binding of the androgen receptor in cell lines and a correlation of their expression with that of the prototypic androgen response gene PSA/KLK3 in cancer tissues. Moreover, DNA methylation of both proviruses was decreased in cancers and histone modifications at their LTRs were similar in cell lines, with more active modifications in an expressing androgenresponsive cell line. One explanation for their differential expression may relate to differences in interactions with cofactors at their LTRs near androgen-binding sites. The requirement for such cofactors is indicated by the experiment in PC-3 cells, in which cotransfection of the androgen receptor was insufficient to restore androgen responsiveness of LTR reporter constructs. In these cells, androgen responsiveness of the rat probasin promoter was also lower than in 22Rv1 cells. PC-3 cells are known to lack several cofactors required for a normal prostatic androgen response, e.g. HOXB13 (32, 33) . A second, but not necessarily alternative explanation arises from the observation that HERV-K_22q11.23 was differentially expressed and methylated between prostate cancers expressing high versus normal levels of ERG, whereas HERVK17 expression and methylation did not differ. Overexpression of ERG has been shown to change androgen responsiveness at individual loci in a differential manner and to affect epigenetic mechanisms of regulation via the EZH2 polycomb protein (34) . The differential regulation of HERV-K_22q11.23 and HERVK17 in prostate cancer appears to represent part of this global change and ought be further investigated in this larger context.
Overexpression of HERV-K_22q11.23 was detectable across the provirus and if pronounced, also led to de novo expression of an additional transcript that might encode a protein homologous to the accessory HERV-K protein, Np9. Some full-length HERV-K proviruses are capable of expressing either of two accessory proteins, Np9 and Rec. Both proteins are inhibitors of the c-MYC repressor, PLZF (35) . Additionally, Np9 influences the Notch signaling pathway by interfering with the Numb inhibitor LNX (36) . In accord with our findings, Np9 expression from HERV-K101 was found restricted to tumor cells, especially testicular and mammary tumors (37) . Interestingly, Rec may influence androgen receptor activity by inhibiting the corepressor TZFP, a PLZF paralogue (38) . Of note, although HERV-K proviruses are considered the most intact and active retroviruses in the human genome (3), transcripts from other families, HERV-R (39) and HERV-E (10,40) have also been detected in prostatic tissues.
Previous studies have demonstrated that LINE-1 hypomethylation in prostate cancer is associated with tumor progression and essentially universal in metastatic cases (5-7). It has not been investigated yet whether this hypomethylation leads to increased expression of fulllength sequences. In fact, only very few investigations comparing LINE-1 expression and methylation in cancer tissues have been published at all (reviewed in 41). According to our pyrosequencing assay aiming at the promoter sequence of full-length elements with potentially intact ORF2, many primary prostate cancers presented diminished methylation, although the decrease was rarely pronounced. This degree of hypomethylation of LINE-1 promoters did not lead to overall increased levels of LINE-1 transcripts as measured by assays aiming at the 5#-region of full-length elements and the 3#-region of consensus sequences. Belancio et al. (20) demonstrated by RNase protection assay that normal prostate tissues predominantly express spliced rather than full-length LINE-1 transcripts. Although that technique is impractical with tissues samples, the ratio of fulllength to spliced transcripts in our sample series can be inferred by comparing the two assays. This comparison suggests that carcinogenesis in the prostate may be accompanied by a shift toward unspliced transcripts from full-length LINE-1 elements rather than an overall increase in transcription. In most prostate cancer cell lines, which are all derived from metastatic cases, LINE-1 promoter methylation was substantially lower than in benign tissues (Table I) . We also observed fewer repressive histone modifications at the LINE-1 promoter in more strongly expressing LNCaP cells compared with PC-3. Nevertheless, the increase in LINE-1 expression was moderate compared with normal PrECs and did not correlate quantitatively with promoter hypomethylation. In summary, therefore, hypomethylation of fulllength LINE-1 elements does occur in prostate cancer, but it is not associated with a major increase in detectable transcripts, especially in cancers at the primary site.
The observed lack of strict correlation between LINE-1 methylation and expression might be explained by recent observations that many expressed LINE-1 elements are located within genes (42, 43) . Investigation of elements expressed in lymphoblastoid cells by RACE and large-scale sequencing revealed that transcription of such intronic elements may occur not only from the internal LINE-1 promoter and that of the surrounding gene but also from start sites located upstream of the retroelement in the same intron. In such cases, the methylation state of a LINE-1 promoter could be irrelevant for transcription. The same study (42) revealed a high interindividual variation in the composition of the LINE-1 'transcriptome' in lymphoblastoid cell lines. The causes of that variation is presently unexplained. To some extent, it may derive from the considerably polymorphy of LINE-1 integrates in humans (44) (45) (46) . These factors could also figure in the patterns of expression in prostatic cells. Finally, DNA methylation is only one of several barriers against LINE-1 retrotransposition (4, 47, 48) . Additional repression mechanisms may act at the chromatin level, as confirmed by our analysis of histone modifications in the cell lines. At a posttranscriptional level editing by APOBECs and rapid mRNA turnover activity may restrain LINE-1 RNA (2).
Transcription of Alu elements has been reported to be increased in cancer cells, like that of more conventional polymerase III transcripts (49) , and is induced by various types of cellular stress (50) . Among the one million elements in the genome, we investigated the evolutionary young and most likely transcriptionally active subfamilies Ya5 and Yb8. Changes in their expression in prostate cancer were limited, with elevated expression of both in prostate cancer cell lines and of Yb8 in individual cancer tissues. These findings require follow-up in larger series and especially in metastases. Because of the limited changes, we did not analyze DNA methylation of Alu sequences. Global sequencing approaches for Alu methylation, currently under development (51-53), will be required to answer the question conclusively how Alu transcription relates to their DNA methylation state.
The results from our study add to the growing recognition that apparently global DNA methylation changes in human cancers affect various sequences to very different extents. Moreover, our findings indicate that hypomethylation of retroelement sequences in cancers cannot generally be taken as an indication of increased expression. Conceivably, differential methylation and expression changes like those reported here for the HERV-K family may also occur among individual LINE-1 sequences and could be discovered using emerging novel sequencing techniques for comprehensive transcriptome and methylation analysis. Precluding the results from such studies in the future, our present analysis, together with previous reports, suggests that the most important retroelements activated in prostate cancer are specific members of the HERV-K family.
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